- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Tesh Khullar Discusses the Emerging Role of Biosimilars in Oncology
Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.
Tesh Khullar, senior vice president & advisor, Flatiron Health, discusses the first to anticancer biosimilars having recently entered the market.
Transcript
With the first 2 anticancer biosimilars having recently entered the market and more waiting to enter, do you think biosimilars will start to play a bigger role in oncology?
I think absolutely. They already have. What we’re seeing on the biosimilar front is actually a greater adoption than most folks thought initially for the non-supportive chemotherapy agents like Avastin, Herceptin, Rituxan. We were thinking maybe a 10% adoption right away. It’s looking more like it’s 15% to 20%. So, I think you’re going to see that trend continue. Biosimilars are going to be here to stay in my opinion and it’s going to be a great opportunity for community oncology.
